Electronic reminders improve compliance with preadmission protocol

An electronic alert system is an effective tool to encourage patients to take preadmission antiseptic showers, which reduces the risk for surgical site infections (SSIs), according to a study from the Journal of the American College of Surgeons.

The findings are significant as SSIs account for about one-third of the $9.8 billion spent annually on hospital-acquired infections, and they are estimated to cause nearly 100,000 deaths per year, according to the study.

Researchers from the Medical College of Wisconsin recruited 80 volunteers, who were randomized to four groups that were all instructed to shower with 4 percent chlorhexidine gluconate (CHG). The system prompted two of the groups to shower via email, text or phone call—one twice and the other three times—while the other two groups received no electronic reminders.

Skin-surface concentrations of CHG were analyzed using colorimetric assay at five separate anatomic sites. Participants were blinded to the randomization code and after final volunteer processing, the code was broken and individual groups were analyzed.

The groups that received electronic reminders had 66 percent and 67 percent higher average concentrations of antiseptic compared to their counterparts.

“However, variation in amount of unused 4% CHG suggests that rigorous standardization is required to maximize the benefits of this patient-centric interventional strategy,” according to study authors.

Read more here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.